Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 6MK.DE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 6MK.DE and 80,000+ other tickers.
See exactly how 6MK.DE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6MK.DE and 80,000+ other tickers.
Merck & Co., Inc. operates as a leading global healthcare enterprise. Its operations are structured into two primary segments: Pharmaceutical and Animal Health. The Pharmaceutical division is dedicated to offering human health solutions, encompassing prescription medicines for critical therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular health, and diabetes. This segment also provides a suite of vaccine products designed for preventive use across pediatric, adolescent, and adult populations. Conversely, the Animal Health segment is…
No recent news available.